# Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

> **NCT04377945** · PHASE2 · TERMINATED · sponsor: **Bukwang Pharmaceutical** · enrollment: 41 (actual)

## Conditions studied

- Dyskinesias
- Parkinson Disease

## Interventions

- **DRUG:** Part 1, JM-010 component Group A
- **DRUG:** Part 1, JM-010 component Group B
- **DRUG:** Part 1, JM-010 component Group C
- **DRUG:** Part 1, Placebo Group
- **DRUG:** Part 2, JM-010 combination Group A
- **DRUG:** Part 2, JM-010 combination Group B
- **DRUG:** Part 2, JM-010 component Group C
- **DRUG:** Part 2, Placebo Group

## Key facts

- **NCT ID:** NCT04377945
- **Lead sponsor:** Bukwang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-28
- **Primary completion:** 2024-02-14
- **Final completion:** 2024-02-14
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04377945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04377945, "Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04377945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*